The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

EU Rejects AstraZeneca Vaccine Contract Claims About Delays

Wed, 27th Jan 2021 10:30

(Alliance News) - A senior EU official on Wednesday contested drug company AstraZeneca PLC's explanation for a delay in vaccine deliveries and stressed Brussels is demanding it fulfil its contract.

The British-Swedish firm has a deal with the European Commission to supply 400 million doses of its coronavirus vaccine, which is a expected to get EU approval on Friday.

But, due to what it said was a production shortfall in the firm's European plants, the firm has warned that it will miss its target, while still meeting a separate contract it signed with the UK.

In an interview on Tuesday, Astra Chief Executive Pascale Soriot said the UK had signed its contract three months earlier than the EU and this had given the firm time to iron out "glitches" in British plants.

"As for Europe, we are three months behind in fixing those glitches. Would I like to do better? Of course," he said.

"One of the plants with the highest yield is in the UK because it started earlier," he said.

"Anyway, we didn't commit with the EU, by the way. It's not a commitment we have to Europe, it's a 'best effort': we said we are going to make our best effort."

But the European official contested that, and warned that Brussels would hold AstraZeneca to its contract.

"We contest many of the things in the interview, including the idea that the factories in the UK are reserved for UK deliveries. It's not true," the EU official said

"On the idea of 'best effort', in the contract we have redundancies. So if there is a problem in a plant in Belgium we have capacity in other plants in Europe and the UK."

The European Commission has not revealed the text of its contract with the firm, citing commercial confidentiality imposed by AstraZeneca, but it is expected to give a detailed response later Wednesday.

source: AFP

Copyright 2021 Alliance News Limited. All Rights Reserved.

Related Shares

More News
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negoti...

29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while a...

29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe a...

29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', ...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.